Rebif New Formulation (RNF) Quality of Life (QOL) Study
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and
injection site redness Rebif treated subjects with relapsing forms of MS who transition to a
new formulation of Rebif (RNF).